Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index by Callagy Grace M, Pharoah Paul D, Pinder Sarah E, Hsu Forrest D, Nielsen Torsten O, Ragaz Joseph, Ellis Ian O, Huntsman David, Caldas Carlos in Clinical cancer research : an official journal of the American Association for Cancer Research (2006).

[PMID: 16638854] PubMed


Prognostication of breast cancer using clinicopathologic variables, although useful, remains imperfect. Many reports suggest that gene expression profiling can refine the current approach. Alternatively, it has been shown that panels of proteins assessed by immunohistochemistry might also be useful in this regard. We evaluate the prognostic potential of a panel of markers by immunohistochemistry in a large case series to establish if either a single marker or a panel could improve the prognostic power of the Nottingham Prognostic Index (NPI). We validated the results in an independent series. Experimental Design and

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.